|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
ATE446955T1
(de)
|
1995-03-30 |
2009-11-15 |
Pfizer Prod Inc |
Chinazolinone derivate
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CN100503580C
(zh)
|
1996-04-12 |
2009-06-24 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
KR100600550B1
(ko)
*
|
2000-10-20 |
2006-07-13 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
|
EP2210607B1
(en)
*
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
WO2006113546A2
(en)
|
2005-04-15 |
2006-10-26 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101353763B1
(ko)
*
|
2005-11-07 |
2014-01-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
|
|
AU2009303602B2
(en)
*
|
2008-10-14 |
2012-06-14 |
Sunshine Lake Pharma Co., Ltd. |
Compounds and methods of use
|
|
TW201920110A
(zh)
|
2009-01-16 |
2019-06-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
|
EP2214019A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
EP2213686A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US10288617B2
(en)
|
2009-10-26 |
2019-05-14 |
Externautics Spa |
Ovary tumor markers and methods of use thereof
|
|
WO2011051278A1
(en)
|
2009-10-26 |
2011-05-05 |
Externautics S.P.A. |
Lung tumor markers and methods of use thereof
|
|
WO2011051276A1
(en)
|
2009-10-26 |
2011-05-05 |
Externautics S.P.A. |
Colon and rectal tumor markers and methods of use thereof
|
|
US20130017546A1
(en)
|
2009-10-26 |
2013-01-17 |
Externautics S.P.A. |
Breast Tumor Markers and Methods of Use Thereof
|
|
US8921058B2
(en)
|
2009-10-26 |
2014-12-30 |
Externautics Spa |
Prostate tumor markers and methods of use thereof
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EP2383578A1
(en)
|
2010-04-30 |
2011-11-02 |
Externautics S.p.A. |
Tumor marker and methods of use thereof
|
|
SG187064A1
(en)
*
|
2010-07-14 |
2013-02-28 |
Zhejiang Beta Pharma Inc |
NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
|
|
WO2012009722A1
(en)
|
2010-07-16 |
2012-01-19 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
US8664244B2
(en)
*
|
2010-09-12 |
2014-03-04 |
Advenchen Pharmaceuticals, LLC |
Compounds as c-Met kinase inhibitors
|
|
HUE045810T2
(hu)
|
2010-09-27 |
2020-01-28 |
Exelixis Inc |
MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
|
|
CN102093421B
(zh)
*
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
TW201309650A
(zh)
|
2011-02-10 |
2013-03-01 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
EP2704717A1
(en)
|
2011-05-02 |
2014-03-12 |
Exelixis, Inc. |
Method of treating cancer and bone cancer pain
|
|
CN102408411B
(zh)
*
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
PL2768796T3
(pl)
|
2011-10-20 |
2020-05-18 |
Exelixis, Inc. |
Sposób wytwarzania pochodnych chinoliny
|
|
WO2013070903A1
(en)
|
2011-11-08 |
2013-05-16 |
Exelixis, Inc. |
Method of quantifying cancer treatment
|
|
MX2014005458A
(es)
|
2011-11-08 |
2015-04-16 |
Exelixis Inc |
Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
|
|
HK1207587A1
(en)
|
2012-05-02 |
2016-02-05 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
JP6513567B2
(ja)
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
GEP20196995B
(en)
|
2013-03-15 |
2019-07-25 |
Inc Exelixis |
Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
|
|
EP2983639A1
(en)
|
2013-04-04 |
2016-02-17 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
ES2927651T3
(es)
|
2013-04-04 |
2022-11-10 |
Exelixis Inc |
Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
US10359428B2
(en)
|
2013-06-14 |
2019-07-23 |
Externautics S.P.A. |
Tumor marker, monoclonal antibodies and methods of use thereof
|
|
AU2014337044A1
(en)
*
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
EA201690912A1
(ru)
|
2013-11-05 |
2016-10-31 |
Когнейт Биосервисис, Инк. |
Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
|
|
EA032757B1
(ru)
|
2014-02-14 |
2019-07-31 |
Экселиксис, Инк. |
Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
|
|
CN106255499A
(zh)
|
2014-03-17 |
2016-12-21 |
埃克塞里艾克西斯公司 |
卡博替尼制剂的给药
|
|
JP6696908B2
(ja)
|
2014-04-25 |
2020-05-20 |
エグゼリクシス， インコーポレイテッド |
肺腺癌の治療方法
|
|
EA033834B1
(ru)
|
2014-07-31 |
2019-11-29 |
Exelixis Inc |
Способ получения кабозантиниба, меченного фтором-18, и его аналогов
|
|
MA40457A
(fr)
|
2014-08-05 |
2017-06-14 |
Exelixis Inc |
Combinaison de médicaments pour traiter le myélome multiple
|
|
CN104817497B
(zh)
*
|
2015-03-20 |
2017-03-08 |
南京众睿缘生物科技有限公司 |
一种炔代喹啉衍生物及其制备方法和用途
|
|
CN106279147A
(zh)
|
2015-05-21 |
2017-01-04 |
中国科学院上海药物研究所 |
一种吡啶并氮杂环化合物及其制备方法和用途
|
|
US20170342033A1
(en)
*
|
2015-06-29 |
2017-11-30 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
US20180009758A1
(en)
*
|
2015-06-29 |
2018-01-11 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
US20160376239A1
(en)
|
2015-06-29 |
2016-12-29 |
Ontogenesis, Llc |
N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
|
|
US11141413B2
(en)
|
2016-04-15 |
2021-10-12 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
MA44733A
(fr)
|
2016-04-19 |
2019-02-27 |
Exelixis Inc |
Procédé de traitement du cancer du sein négatif triple
|
|
CN105797123A
(zh)
*
|
2016-05-18 |
2016-07-27 |
王超 |
一种治疗不孕不育的中药组合物
|
|
CN106400155A
(zh)
*
|
2016-08-31 |
2017-02-15 |
飞佛特种纺织品（宁波）有限公司 |
一种防老化阳光面料
|
|
CN110437145A
(zh)
*
|
2016-09-13 |
2019-11-12 |
上海翔锦生物科技有限公司 |
酪氨酸激酶抑制剂及其应用
|
|
AU2017336547A1
(en)
|
2016-09-27 |
2019-05-02 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method of treating urothelial carcinoma and other genitourinary malignancies using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
UA126970C2
(uk)
|
2017-01-20 |
2023-03-01 |
Екселіксіс, Інк. |
Комбінації кабозантинібу і атезолізумабу для лікування раку
|
|
US10800741B2
(en)
*
|
2017-02-07 |
2020-10-13 |
Ancureall Pharmaceutical (Shanghai) Co., Ltd. |
Quinoline compound, preparation method and medical use therefor
|
|
MX2019012505A
(es)
|
2017-05-26 |
2019-12-19 |
Exelixis Inc |
Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
|
|
US11504362B2
(en)
|
2017-06-09 |
2022-11-22 |
Exelixis, Inc. |
Liquid dosage forms to treat cancer
|
|
SG11202005719UA
(en)
*
|
2017-12-20 |
2020-07-29 |
Angex Pharmaceutical Inc |
Carbamate and urea compounds as multikinase inhibitors
|
|
US20190262330A1
(en)
|
2017-12-21 |
2019-08-29 |
Exelixis, Inc. |
Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
HRP20251184T1
(hr)
*
|
2018-01-26 |
2025-12-05 |
Exelixis, Inc. |
Spojevi za liječenje poremećaja ovisnih o kinazi
|
|
AU2019212800B2
(en)
*
|
2018-01-26 |
2024-05-23 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
SG11202006945PA
(en)
*
|
2018-01-26 |
2020-08-28 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
PL3894012T4
(pl)
*
|
2018-12-13 |
2026-01-05 |
Exelixis, Inc. |
Postacie krystaliczne i postacie soli inhibitora kinazy
|
|
EP3914356A1
(en)
*
|
2019-01-25 |
2021-12-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
KR102826380B1
(ko)
*
|
2019-06-03 |
2025-06-26 |
엑셀리시스, 인코포레이티드 |
카이네이스 저해제의 결정질 염 형태
|
|
AR119069A1
(es)
*
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
FI4143169T3
(fi)
*
|
2020-04-30 |
2026-06-08 |
Exelixis Inc |
Kinaasi-inhibiittorin valmistusmenetelmät
|
|
PH12023550160A1
(en)
*
|
2020-07-31 |
2023-09-18 |
Exelixis Inc |
Combinations for the Treatment of Cancer
|
|
IL302485A
(en)
*
|
2020-11-05 |
2023-06-01 |
Exelixis Inc |
Kinase inhibitor pharmaceutical preparations
|
|
AR127561A1
(es)
*
|
2021-11-03 |
2024-02-07 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de cinasas
|
|
AU2022420610A1
(en)
*
|
2021-12-22 |
2024-06-27 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|